Moderna is developing an experimental dose booster for the new variants

New York: Moderna said, Wednesday, that it is working with scientists in the US government to study an experimental booster dose targeting a new type of Corona virus, and has raised the goal of producing the global Covid-19 vaccine for this year by 100 million doses.

The US biotech company has produced a raw material for a booster dose intended to treat the type of virus that was first detected in South Africa that may be more resistant to existing vaccines.

I shipped the vaccine to the US National Institutes of Health, which helped develop a modern vaccine, for additional study.

Moderna is experimenting with several potential methods to combat new variants of the virus.

It includes an additional booster dose targeting the type now prevalent in South Africa and spreading globally, a combined booster dose that mixes the current Covid-19 vaccine with an experimental vaccine, and an additional booster vaccine above the current two-dose vaccine. , The company said.

It will also try using the experimental vaccine and co-vaccination as the primary vaccines against Covid-19, and give two doses to people who have not yet received an injection and have not had an infection.

The United States discovered its first case of the South African type in January, and it has since appeared in 14 states, according to US government data.

Several studies indicate that it is more resistant to existing vaccines than other variants of the Corona virus.

Moderna has also raised its projected vaccine production for 2021 to 700 million doses globally from 600 million and is exploring further improvements to the manufacturing process that could lift production this year to as much as one billion doses.

The company said it was also investing in additional manufacturing capacity that would raise its global production for 2022 to around 1.4 billion doses, from a previous forecast of 1.2 billion.

Moderna said it usually takes six to nine months to develop a new manufacturing facility and additional time after that for regulatory checks and to ramp up production.

Moderna has shipped a total of about 60 million doses to date, 55 million of which have gone to the United States. The company said it was still ramping up its supply chain for global shipments.

Wednesday’s announcements come ahead of a planned investor call on Thursday morning.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button